su011248
Carcinoma, Thymic
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Carcinoma, Thymic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
Panobinostat National Cancer Institute (NCI) | Phase 2 | B |
Lapatinib National Cancer Institute (NCI) | Phase 2 | CCC |
mk-2206 National Cancer Institute (NCI) | Phase 2 | CCC |
kfa115 Novartis Pharmaceuticals | Phase 1 | CC |
Epirubicin Novartis Pharmaceuticals | Phase 1 | CC |
Pembrolizumab Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →